Granulocyte and granulocyte-macrophage colony stimulating factors for newly diagnosed patients with myelodysplastic syndromes

  • Protocol
  • Intervention

Authors

  • Franz Hutzschenreuter,

    1. University Hospital of Cologne, Cochrane Haematological Malignancies Group, Department I of Internal Medicine, Cologne, Germany
    Search for more papers by this author
  • Nicole Skoetz,

    1. University Hospital of Cologne, Cochrane Haematological Malignancies Group, Department I of Internal Medicine, Cologne, Germany
    Search for more papers by this author
  • Ina Monsef,

    1. University Hospital of Cologne, Cochrane Haematological Malignancies Group, Department I of Internal Medicine, Cologne, Germany
    Search for more papers by this author
  • Karl-Anton Kreuzer,

    1. University Hospital of Cologne, Department I of Internal Medicine, Cologne, Germany
    Search for more papers by this author
  • Andreas Engert,

    1. University Hospital of Cologne, Cochrane Haematological Malignancies Group, Department I of Internal Medicine, Cologne, Germany
    Search for more papers by this author
  • Kathrin Bauer

    Corresponding author
    1. University Hospital of Cologne, Cochrane Haematological Malignancies Group, Department I of Internal Medicine, Cologne, Germany
    • Kathrin Bauer, Cochrane Haematological Malignancies Group, Department I of Internal Medicine, University Hospital of Cologne, Kerpener Str. 62, Cologne, 50924, Germany. kathrin.bauer@uk-koeln.de.

    Search for more papers by this author

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

The main objective of this review is to assess the benefits of G-CSF and GM-CSF for the treatment of patients with MDS with regard to overall survival, progression-free survival, tumour response to additional chemotherapy, adverse events (from G-CSF and GM-CSF), risk and duration of neutropenia, infections and anaemia, frequency of blood product transfusions, risk and duration of antibiotic treatment, hospitalisation, quality of life (QoL) and time to progression to AML. For this purpose we will critically, systematically and statistically analyse the efficacy of G-CSF and GM-CSF compared to no treatment or placebo.